Intrinsic value of Enzo Biochem - ENZ

Previous Close

$8.80

  Intrinsic Value

$13.20

stock screener

  Rating & Target

buy

+50%

Previous close

$8.80

 
Intrinsic value

$13.20

 
Up/down potential

+50%

 
Rating

buy

We calculate the intrinsic value of ENZ stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2017), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.4

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2017(a)
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046
   2047

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  4.85
  3.70
  3.83
  3.95
  4.05
  4.15
  4.23
  4.31
  4.38
  4.44
  4.50
  4.55
  4.59
  4.63
  4.67
  4.70
  4.73
  4.76
  4.78
  4.80
  4.82
  4.84
  4.86
  4.87
  4.88
  4.90
  4.91
  4.92
  4.92
  4.93
  4.94
Revenue, $m
  108
  112
  116
  121
  126
  131
  137
  142
  149
  155
  162
  170
  177
  186
  194
  203
  213
  223
  234
  245
  257
  269
  282
  296
  311
  326
  342
  359
  376
  395
  414
Variable operating expenses, $m
 
  61
  63
  66
  69
  71
  74
  78
  81
  84
  88
  92
  96
  100
  105
  110
  115
  120
  126
  132
  139
  145
  152
  160
  168
  176
  184
  194
  203
  213
  224
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  111
  61
  63
  66
  69
  71
  74
  78
  81
  84
  88
  92
  96
  100
  105
  110
  115
  120
  126
  132
  139
  145
  152
  160
  168
  176
  184
  194
  203
  213
  224
Operating income, $m
  -3
  51
  53
  55
  57
  60
  62
  65
  68
  71
  74
  78
  82
  85
  89
  94
  98
  103
  108
  113
  118
  124
  130
  136
  143
  150
  157
  165
  173
  182
  191
EBITDA, $m
  1
  54
  56
  58
  61
  63
  66
  69
  72
  75
  78
  82
  85
  89
  94
  98
  103
  108
  113
  118
  124
  130
  136
  143
  150
  157
  165
  173
  181
  190
  200
Interest expense (income), $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  2
  2
  2
Earnings before tax, $m
  -2
  51
  53
  55
  57
  59
  62
  65
  68
  71
  74
  78
  81
  85
  89
  93
  97
  102
  107
  112
  117
  123
  129
  135
  142
  149
  156
  164
  172
  180
  189
Tax expense, $m
  1
  14
  14
  15
  15
  16
  17
  17
  18
  19
  20
  21
  22
  23
  24
  25
  26
  28
  29
  30
  32
  33
  35
  37
  38
  40
  42
  44
  46
  49
  51
Net income, $m
  -3
  37
  39
  40
  42
  43
  45
  47
  49
  51
  54
  57
  59
  62
  65
  68
  71
  75
  78
  82
  86
  90
  94
  99
  104
  109
  114
  119
  125
  132
  138

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  64
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  108
  46
  47
  49
  51
  53
  56
  58
  61
  63
  66
  69
  72
  76
  79
  83
  87
  91
  95
  100
  105
  110
  115
  121
  127
  133
  139
  146
  153
  161
  169
Adjusted assets (=assets-cash), $m
  44
  46
  47
  49
  51
  53
  56
  58
  61
  63
  66
  69
  72
  76
  79
  83
  87
  91
  95
  100
  105
  110
  115
  121
  127
  133
  139
  146
  153
  161
  169
Revenue / Adjusted assets
  2.455
  2.435
  2.468
  2.469
  2.471
  2.472
  2.446
  2.448
  2.443
  2.460
  2.455
  2.464
  2.458
  2.447
  2.456
  2.446
  2.448
  2.451
  2.463
  2.450
  2.448
  2.445
  2.452
  2.446
  2.449
  2.451
  2.460
  2.459
  2.458
  2.453
  2.450
Average production assets, $m
  12
  12
  12
  13
  13
  14
  14
  15
  16
  16
  17
  18
  19
  20
  21
  22
  23
  24
  25
  26
  27
  29
  30
  31
  33
  35
  36
  38
  40
  42
  44
Working capital, $m
  71
  7
  8
  8
  8
  9
  9
  9
  10
  10
  11
  11
  12
  12
  13
  13
  14
  15
  15
  16
  17
  18
  18
  19
  20
  21
  22
  23
  24
  26
  27
Total debt, $m
  1
  2
  2
  3
  4
  5
  6
  7
  8
  9
  11
  12
  13
  15
  16
  18
  19
  21
  23
  25
  27
  29
  32
  34
  37
  39
  42
  45
  48
  51
  55
Total liabilities, $m
  19
  20
  20
  21
  22
  23
  24
  25
  26
  27
  29
  30
  31
  33
  34
  36
  37
  39
  41
  43
  45
  47
  50
  52
  55
  57
  60
  63
  66
  69
  73
Total equity, $m
  89
  26
  27
  28
  29
  30
  32
  33
  34
  36
  38
  39
  41
  43
  45
  47
  49
  52
  54
  57
  59
  62
  65
  69
  72
  75
  79
  83
  87
  91
  96
Total liabilities and equity, $m
  108
  46
  47
  49
  51
  53
  56
  58
  60
  63
  67
  69
  72
  76
  79
  83
  86
  91
  95
  100
  104
  109
  115
  121
  127
  132
  139
  146
  153
  160
  169
Debt-to-equity ratio
  0.011
  0.070
  0.090
  0.120
  0.140
  0.170
  0.190
  0.210
  0.240
  0.260
  0.280
  0.300
  0.320
  0.340
  0.360
  0.380
  0.400
  0.410
  0.430
  0.440
  0.460
  0.470
  0.490
  0.500
  0.510
  0.520
  0.530
  0.540
  0.550
  0.560
  0.570
Adjusted equity ratio
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -3
  37
  39
  40
  42
  43
  45
  47
  49
  51
  54
  57
  59
  62
  65
  68
  71
  75
  78
  82
  86
  90
  94
  99
  104
  109
  114
  119
  125
  132
  138
Depreciation, amort., depletion, $m
  4
  3
  3
  3
  3
  3
  4
  4
  4
  4
  4
  4
  4
  4
  4
  4
  5
  5
  5
  5
  5
  6
  6
  6
  7
  7
  7
  8
  8
  8
  9
Funds from operations, $m
  -5
  40
  42
  43
  45
  47
  49
  51
  53
  55
  58
  60
  63
  66
  69
  72
  76
  79
  83
  87
  91
  96
  100
  105
  110
  116
  121
  127
  133
  140
  147
Change in working capital, $m
  -5
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
Cash from operations, $m
  0
  40
  41
  43
  45
  47
  48
  51
  53
  55
  57
  60
  63
  65
  68
  72
  75
  79
  82
  86
  90
  95
  99
  104
  109
  115
  120
  126
  132
  139
  146
Maintenance CAPEX, $m
  0
  -2
  -2
  -2
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -4
  -4
  -4
  -4
  -4
  -5
  -5
  -5
  -5
  -5
  -6
  -6
  -6
  -7
  -7
  -7
  -8
  -8
  -8
New CAPEX, $m
  -2
  0
  0
  0
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -2
  -2
  -2
  -2
  -2
  -2
  -2
Cash from investing activities, $m
  -2
  -2
  -2
  -2
  -4
  -4
  -4
  -4
  -4
  -4
  -4
  -4
  -5
  -5
  -5
  -5
  -5
  -6
  -6
  -6
  -6
  -6
  -7
  -7
  -8
  -9
  -9
  -9
  -10
  -10
  -10
Free cash flow, $m
  -2
  37
  39
  40
  42
  43
  45
  47
  49
  51
  53
  56
  58
  61
  64
  67
  70
  73
  76
  80
  84
  88
  92
  97
  101
  106
  112
  117
  123
  129
  135
Issuance/(repayment) of debt, $m
  -2
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  2
  2
  2
  2
  2
  2
  2
  2
  2
  2
  3
  3
  3
  3
  3
  3
  3
Issuance/(repurchase) of shares, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  -2
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  2
  2
  2
  2
  2
  2
  2
  2
  2
  2
  3
  3
  3
  3
  3
  3
  3
Total cash flow (excl. dividends), $m
  -4
  38
  39
  41
  43
  44
  46
  48
  50
  52
  55
  57
  60
  62
  65
  68
  71
  75
  78
  82
  86
  90
  95
  99
  104
  109
  114
  120
  126
  132
  139
Retained Cash Flow (-), $m
  1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -3
  -3
  -3
  -3
  -3
  -3
  -4
  -4
  -4
  -4
  -4
  -5
Prev. year cash balance distribution, $m
 
  64
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  101
  38
  40
  41
  43
  45
  47
  49
  51
  53
  55
  58
  60
  63
  66
  69
  72
  76
  79
  83
  87
  92
  96
  101
  105
  111
  116
  122
  128
  134
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  97
  35
  35
  34
  33
  33
  32
  30
  29
  28
  26
  25
  23
  21
  19
  18
  16
  14
  12
  11
  9
  8
  6
  5
  4
  3
  2
  2
  1
  1
Current shareholders' claim on cash, %
  100
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

Enzo Biochem, Inc. is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company's segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. It offers a menu of molecular and other clinical laboratory tests or procedures. Enzo Life Sciences manufactures, develops and markets products and tools to clinical research, drug development and bioscience research customers. Enzo Therapeutics is a biopharmaceutical venture that develops multiple approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases. Its products in the development pipeline include a range of assays for detection of various women's health infectious agents, as well as for use in the identification of pathogens for other markets.

FINANCIAL RATIOS  of  Enzo Biochem (ENZ)

Valuation Ratios
P/E Ratio -136.4
Price to Sales 3.8
Price to Book 4.6
Price to Tangible Book
Price to Cash Flow 0
Price to Free Cash Flow -204.6
Growth Rates
Sales Growth Rate 4.9%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 0%
Cap. Spend. - 3 Yr. Gr. Rate 14.9%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 1.1%
Total Debt to Equity 1.1%
Interest Coverage 0
Management Effectiveness
Return On Assets -2.7%
Ret/ On Assets - 3 Yr. Avg. 14.7%
Return On Total Capital -3.3%
Ret/ On T. Cap. - 3 Yr. Avg. 19%
Return On Equity -3.4%
Return On Equity - 3 Yr. Avg. 19.8%
Asset Turnover 1
Profitability Ratios
Gross Margin 44.4%
Gross Margin - 3 Yr. Avg. 44.3%
EBITDA Margin 1.9%
EBITDA Margin - 3 Yr. Avg. 17.8%
Operating Margin -2.8%
Oper. Margin - 3 Yr. Avg. 13.9%
Pre-Tax Margin -1.9%
Pre-Tax Margin - 3 Yr. Avg. 13.9%
Net Profit Margin -2.8%
Net Profit Margin - 3 Yr. Avg. 13%
Effective Tax Rate -50%
Eff/ Tax Rate - 3 Yr. Avg. -15.2%
Payout Ratio 0%

ENZ stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the ENZ stock intrinsic value calculation we used $108 million for the last fiscal year's total revenue generated by Enzo Biochem. The default revenue input number comes from 2017 income statement of Enzo Biochem. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our ENZ stock valuation model: a) initial revenue growth rate of 3.7% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for ENZ is calculated based on our internal credit rating of Enzo Biochem, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Enzo Biochem.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of ENZ stock the variable cost ratio is equal to 54.6%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for ENZ stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for Enzo Biochem.

Corporate tax rate of 27% is the nominal tax rate for Enzo Biochem. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the ENZ stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for ENZ are equal to 10.6%.

Life of production assets of 4.6 years is the average useful life of capital assets used in Enzo Biochem operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for ENZ is equal to 6.5%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $89 million for Enzo Biochem - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 46.548 million for Enzo Biochem is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Enzo Biochem at the current share price and the inputted number of shares is $0.4 billion.

RELATED COMPANIES Price Int.Val. Rating
DGX Quest Diagnost 97.14 119.06  buy
LH Laboratory of 156.26 145.26  hold
NEO NeoGenomics 9.11 1.26  str.sell
PMD Psychemedics 20.35 20.02  hold
CBMX CombiMatrix 6.25 95.13  str.buy
OPGN OpGen 0.200 0.01  str.sell
QGEN Qiagen 32.05 16.45  str.sell

COMPANY NEWS

▶ Enzo Biochem, Inc. to Host Earnings Call   [Dec-08-17 07:00AM  ACCESSWIRE]
▶ Enzo Biochem reports 1Q loss   [Dec-07-17 04:15PM  Associated Press]
▶ Top 5 Biotech Stocks for 2017   [Dec-06-17 04:50PM  Investopedia]
▶ Top 5 Biotech Stocks for 2017   [Oct-12-17 02:35PM  Investopedia]
▶ Enzo Biochem posts 4Q profit   [Sep-27-17 09:16PM  Associated Press]
▶ Enzo Biochem posts 4Q profit   [04:16PM  Associated Press]
▶ ETFs with exposure to Enzo Biochem, Inc. : July 10, 2017   [Jul-10-17 02:25PM  Capital Cube]
▶ BeiGene (BGNE) Surges: Stock Moves 20.8% Higher   [Jul-05-17 08:33AM  Zacks]
▶ Enzo Biochem Reports Delaware Court Ruling   [Jun-29-17 08:00AM  Business Wire]
▶ 5 Biomedical Stocks That Are Expected To Surge   [Jun-27-17 12:41PM  Zacks]
▶ ETFs with exposure to Enzo Biochem, Inc. : June 19, 2017   [Jun-19-17 03:17PM  Capital Cube]
▶ ETFs with exposure to Enzo Biochem, Inc. : June 9, 2017   [Jun-09-17 01:28PM  Capital Cube]
▶ Enzo Biochem posts 3Q loss   [Jun-08-17 04:28PM  Associated Press]
▶ ETFs with exposure to Enzo Biochem, Inc. : May 30, 2017   [May-30-17 12:26PM  Capital Cube]
▶ ETFs with exposure to Enzo Biochem, Inc. : May 19, 2017   [May-19-17 01:51PM  Capital Cube]
▶ ETFs with exposure to Enzo Biochem, Inc. : May 8, 2017   [May-08-17 04:28PM  Capital Cube]
▶ ETFs with exposure to Enzo Biochem, Inc. : April 27, 2017   [Apr-27-17 03:57PM  Capital Cube]
▶ ETFs with exposure to Enzo Biochem, Inc. : April 17, 2017   [Apr-17-17 12:53PM  Capital Cube]
▶ ETFs with exposure to Enzo Biochem, Inc. : April 5, 2017   [Apr-05-17 04:42PM  Capital Cube]
Financial statements of ENZ
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.